South Korea’s biotechnology leader, Samsung Biologics, has announced plans to acquire Swiss peptide drug manufacturer PolyPeptide Group in a deal valued at approximately $1.8 billion. The proposed acquisition represents the company’s largest overseas investment to date and reflects its strategy to broaden its capabilities in the rapidly growing pharmaceutical manufacturing market. Strengthening Presence in Advanced… Continue reading Samsung Biologics Expands Global Footprint with Planned Acquisition of Swiss Drug Manufacturer
Data-driven market news & analysis